Category Archives: Uncategorized

13 Sep

Bloomberg Exposes How Drug Cost Middlemen “Rake in Millions”

Bloomberg has authored an investigative piece exposing drug cost middlemen, better known as pharmacy benefit managers (PBMs), for their role

12 Sep

Gilead Partners with Precision Bio in Search of Gene-Editing HBV Cure

Gilead Sciences is turning to gene editing in its effort to develop a cure for hepatitis B virus infections-DNA-cutting enzymes

12 Sep

Nebraska City plans Twitter town hall

Nebraska City’s City Council, Mayor Bryan Bequette and other officials will participate in the city’s first-ever Twitter town hall meeting

12 Sep

Call for proposals for ERC Proof of Concept Grant

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: ERC-2018-PoCPillar: Excellent ScienceOpening Date: Deadline: Tue, 11 Sep 2018 17:00:00 (Brussels local time)Modification Date: Wed, 12 Sep

11 Sep

Andrew Cheng Departs Gilead Sciences for Akero Therapeutics CEO Post

Andrew Cheng has been appointed president and CEO of Cambridge, MA-based Akero Therapeutics. Cheng comes to Akero following a nearly

11 Sep

Research Headlines – Shaping the future of Europe’s energy policy

[Source: Research & Innovation] The transition toward clean, efficient and secure energy will require more than just technological innovation. An

11 Sep

Greenwood Highlights Role of Innovation in Solving Opioid Crisis

The numbers are staggering. The opioid epidemic is costing our nation more than $500 billion annually in health and social costs. What’s

11 Sep

OncoResponse Nabs $40M for Cancer Drugs Based On Survivors’ Antibodies

Houston-OncoResponse, a Seattle biotech startup formed jointly with the University of Texas M.D. Anderson Cancer Center in Houston, announced Tuesday

10 Sep

Sustainable and circular Bioeconomy, the European way – 22 October 2018, Brussels, Belgium

[Source: Research & Innovation] The emerging bioeconomy is moving from research niche to market norm and Europe needs to maintain

10 Sep

The Patient Perspective-Valuable for Drug Development

Congress, the Food and Drug Administration (FDA), drug developers, researchers and patient groups have all recognized the contribution patients and